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Abstract
Pancreatic ductal adenocarcinoma is the fourth leading cause of cancer death worldwide, with no satisfactory treatment to
date. In this study, we tested whether the combined inhibition of cyclooxygenase-2 (COX-2) and class I histone deacetylase
(HDAC) may results in a better control of pancreatic ductal adenocarcinoma. The impact of the concomitant HDAC and
COX-2 inhibition on cell growth, apoptosis and cell cycle was assessed first in vitro on human pancreas BxPC-3, PANC-1 or
CFPAC-1 cells treated with chemical inhibitors (SAHA, MS-275 and celecoxib) or HDAC1/2/3/7 siRNA. To test the potential
antitumoral activity of this combination in vivo, we have developed and characterized, a refined chick chorioallantoic
membrane tumor model that histologically and proteomically mimics human pancreatic ductal adenocarcinoma. The
combination of HDAC1/3 and COX-2 inhibition significantly impaired proliferation of BxPC-3 cells in vitro and stalled entirely
the BxPC-3 cells tumor growth onto the chorioallantoic membrane in vivo. The combination was more effective than either
drug used alone. Consistently, we showed that both HDAC1 and HDAC3 inhibition induced the expression of COX-2 via the
NF-kB pathway. Our data demonstrate, for the first time in a Pancreatic Ductal Adenocarcinoma (PDAC) model, a significant
action of HDAC and COX-2 inhibitors on cancer cell growth, which sets the basis for the development of potentially effective
new combinatory therapies for pancreatic ductal adenocarcinoma patients.
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Introduction
Pancreatic ductal adenocarcinoma (PDAC) lists among the most
deadly form of cancers [1]. Early-stage of the disease is clinically
silent and the diagnosis of the disease is mostly made at an
advanced stage. This late diagnosis contributes to one of the lowest
5-year survival rate (only 3%) [2]. Today PDAC are treated by
surgery and/or adjuvant therapy with gemcitabine, increasing
only slightly the median survival of the patients. There is therefore
an urgent need to develop new effective therapies for PDAC
patients.
There are abundant evidence indicating that deregulation of
histone acetylation contributes to pancreas cancer development
and progression [3]. Histone deacetylases (HDAC) represent a
family of enzymes that regulate paramount cellular activities
including epigenetic silencing of tumor suppressor genes and
modulation of protein functions. We and others have shown that
HDAC inhibition exerts both anti-cancer and anti-angiogenesis
activities [4–6]. HDAC expression is altered in PDAC, including
HDAC1, HDAC2, HDAC3 and HDAC7 [7–10]. Preclinical
studies have suggested that HDAC inhibition hold significant
potential for the development of new anticancer therapies [11].
Accordingly, several HDAC inhibitors have been recently
approved by the Food and Drug Administration for the treatment
of Cutaneous T-Cell Lymphoma while new molecules are
currently in phase III clinical trials. However, when used in
monotherapy, HDAC inhibitors showed limited efficacy in various
solid malignancies, including PDAC [3,12,13]. Indeed, LAQ824
or MS-275 have been evaluated in phase I clinical trials in solid
cancers, including PDAC, without any objective clinical response
[14,15]. Alternatively, HDAC inhibitors have been used in
combined therapy strategies [16,17], with some combinations
generating promising effects for human PDAC in vitro [18–21] or
in experimental tumors [22]. Unfortunately, these results do not
translate in clinical trials [23,24].
The lack of efficacy of HDAC inhibitors in pancreatic cancer
could be linked to the pleiotropic activities of HDACs in cell
biology [25,26] leading to undesired pro-cancer effects. For
example, a recent study demonstrated that pan-HDAC inhibitors
induce cyclooxygenase-2 (COX-2) expression in lung cancer cells,
leading to a stimulation of endothelial cell proliferation [27]. Since
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COX-2 has been also associated to pancreatic cancer cell
proliferation [28] or tumor growth [29–31], we hypothesized that
COX-2 overexpression may also be induced in PDAC when
treated with HDAC inhibitors, leading to reduced efficiency and
hence therapeutic failure.
To test the biological relevance of combining class I HDAC and
COX-2 inhibitors in vivo, we devised a refined PDAC chick
chorioallantoic membrane (CAM) model based on our previous
work [32]. The CAM model has been successfully used with
several cell lines to produce tumors [33,34]. Similarly to the
murine model, most steps of tumor progression are recapitulated
in a very short period of time [35]. Previously, BxPC-3 pancreatic
cancer cells were already demonstrated to produce vascularized
100 mm long tumor nodes on CAM [32]. However, the small size
of the nodules represented a significant limitation for structural
observation, accurate volume evaluation and study of drug
efficacy. Here, we have established and implemented a refined
BxPC-3 PDAC model featuring a dramatic increase (64-fold) in
tumor size and displaying structural architecture and protein
expression mimicking human PDAC. This model was successfully
exploited to demonstrate that the combination of class I HDAC




BxPC-3 (ATCC CRL-1687), PANC-1 (ATCC CRL-1469) and
CFPAC-1 (ATCC CRL-1918) are human pancreatic cancer cell
lines derived respectively from PDAC [36], pancreas duct
epithelioid carcinoma [37] and PDAC liver metastasis [38].
BxPC-3 were a generous gift from Prof. Bikfalvi (Inserm u1029,
Bordeaux, France), Panc-1 were a generous gift from Prof. Muller
and Burtea (NMR Laboratory, University of Mons, Belgium).
CFPAC-1 were bought from ATCC. Celecoxib was obtained from
the University Pharmacy (Kemprotec Ltd, Middlesbrough, UK).
MS-275 and SAHA were purchased from Enzo Life Sciences
(Antwerpen, Belgium). Other chemicals were purchased from
Sigma (Bornem, Belgium).
Cell culture
BxPC-3 human pancreatic cancer cell line were maintained in
RPMI1640 medium supplemented with glucose (2.5 g/L), sodium
pyruvate (1 mM) and FBS (10%). PANC-1 were maintained in
DMEM supplemented with FBS (10%). CFPAC-1 were main-
tained in Iscove’s Modified Dulbecco’s Medium with FBS (10%).
Cells were treated with MS-275, celecoxib or combination of both
as well as with suberoylanilide hydroxamic acid (SAHA) solubi-
lized in medium with 0.1% DMSO.
Small interfering RNA transfection
HDAC-specific small interfering RNA (siRNA) were synthe-
sized by Eurogentec (Seraing, Belgium). NF-kB p65 SMARTpool
siRNA were bought from Thermo Fisher-Dharmacon (Whaltham,
MA). Lipofectamine-mediated transfections were performed at a
siRNA concentration of 40 nM following manufacturer’s recom-
mendations (Life Technologies, Carlsbad, NM). GL3 was an
irrelevant siRNA targeting luciferase. siRNA sequences were
published previously [5].
Cell growth
Equal densities of cells were seeded in complete medium and
were harvested at the indicated time-points. The cell numbers
were indirectly determined using Hoechst incorporation. Results
were expressed as DNA content.
Western-blotting
BxPC-3 cells or frozen tumors were disrupted in lysis buffer (1%
SDS, 40 mM Tris-HCl pH7.5) in the presence of protease and
phosphatase inhibitors. Proteins were separated by SDS-PAGE
(6–12.5%) then electrotransfered on nitrocellulose membranes.
Following primary antibodies were used: anti-COX-2 (Cayman
Chemicals, Ann Arbor, MI), anti-HDAC1 (Cell Signalling,
Danvers, MA), anti-HDAC2 (Santa Cruz Biotechnology, Santa
Cruz, CA), anti-HDAC3 (Cell Signalling, Danvers, MA), anti-
acetylated-Histone-3 (Millipore, Billerica, MA), anti-HDAC7
(Santa Cruz Biotechnology, Santa Cruz, CA), anti-phospho-IkBa
(Cell Signalling, Danvers, MA), anti-p65 (Cell signaling, Danvers,
MA), anti-p21 (Santa Cruz Biotechnology, Santa Cruz, CA), anti-
p27 (BD Biosciences, Franklin Lakes, NJ), anti-pRB (BD
Biosciences, Franklin Lakes, NJ), anti-E2F1 (Santa Cruz Biotech-
nology, Santa Cruz, CA), anti-MEK2 (Cell signaling, Danvers,
MA), anti-ORC2 (Cell signaling, Danvers, MA), anti-caspase-3
(Cell Signalling, Danvers, MA) and anti-HSC70 (Santa Cruz
Biotechnology, Santa Cruz, CA). Immunodetection was per-
formed using appropriate secondary antibody conjugated with
horseradish peroxidase.
Quantitative real-time RT-PCR
Total RNA extraction and quantitative real-time RT-PCR were
performed as previously described [39]. Human COX-2 expres-
sion was detected using a commercial RT-qPCR TaqMan assay
(Hs00153133-m1; Applied Biosystems, Carlsbad, NM). Human
IL-8 expression was detected using specific forward (59-GAAG-
GAACCATCTCACTGTGTGTAA-39) and reverse (59-ATCAG-
GAAGGCTGCCAAGAG-39) primers synthesized by Eurogentec
(Seraing, Belgium).
Annexin V/propidium iodide staining
Apoptotic cells were determined by annexin V-FITC and non-
vital dye propidium iodide (PI) staining with a FITC-Annexin V
apoptosis detection kit I (BD Biosciences, Franklin Lakes, NJ)
according to the manufacturer’s instructions. Flow cytometry was
performed on a FACSCalibur IITM and samples were analyzed
using CellQuestTM software (BD Biosciences, Franklin Lakes, NJ).
Cell cycle analysis
The relative percentage of cells in each stage of the cell cycle
was analyzed as previously described [33] by flow cytometric
analysis with FACSCalibur IITM and ModFit LTTMprogram.
Tumor growth on CAM
Fertilized chicken eggs were opened as previously described
[32]. On post-fertilization day 11, CAM surface was gently
scratched with a needle and 3.56106 BxPC-3, PANC-1 or
CFPAC-1 cells in suspension with 50% matrigel in a final volume
of 100 mL were grafted on the CAM enclosed by a 6-mm plastic
ring. The implantation day was considered as day 0 of tumor
development. Drugs (celecoxib 8 mM and/or MS-275 0.2 mM in a
30 ml final volume) were applied daily directly on tumor starting at
day 2. At day 7, the tumors were excised from the CAM and
digital pictures were taken using a stereomicroscope. Tumor
volume was calculated using an ellipsoid formula: Volu-
me = (46pxZ16Z26Z3)/3 where Z123 are the main radius of
the tumor.
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Ethics statement
All animal experiments were approved by the Animal Welfare
Committee of the University of Lie`ge (approval #1278).
Histology procedure
BxPC-3 tumors were washed in PBS and then fixed in 4%
paraformaldehyde for 30min at 4uC. The tumors were embedded
in paraffin and 5 mm sections were stained with Hematoxylin-
eosin or Masson’s trichrome.
Immunoperoxydase and amylase-periodic acid Schiff (PAS)
staining were performed on 5 mm sections, respectively, with the
BenchMark XT IHC/ISH automated stainer and the NexES
Special Stains (Ventana Medical Systems Inc, Tucson, AZ)
according to the manufacturer’s instructions. Following antibodies
were used: anti-cytokeratin 7 (CK7 - Dako, Glostrup, Denmark),
anti-cytokeratin 19 (CK19 - Roche Diagnostics, Vilvoorde,
Belgium), anti-cytokeratin 20 (CK20 - Dako, Glostrup, Denmark),
anti-CD56 (Novocastra, Leica Microsystem Inc, Buffalo Grove,
IL), anti-carcinoembryonic antigen (CEA - Roche Diagnostics,
Vilvoorde, Belgium), anti-Ki67 (Dako, Glostrup, Denmark), anti-
latent transforming growth factor-beta binding protein 2 (LTBP2
– Santa Cruz Biotchnology, Santa Cruz, CA), anti-transforming
growth factor beta-induced (TGFBI - Cell Signalling, Danvers,
MA), anti-myoferlin (Sigma, Bornem, Belgium) and anti-desmin
(Dako, Glostrup, Denmark) were used for the primary reaction.
Ki67 quantification was performed on randomly taken pictures
(3 pictures from each tumor, 3 tumors in each experimental
group). After channel splitting, blue channel pictures were
binarized according to the brightness. The size of the area
occupied by all cells or by Ki67-positive cells was measured using
imageJ 1.46r software.
In order to visualize the tumor vasculature, thick rehydrated
tissue sections (35 mm) were incubated for 30min in the dark with
0.05% Triton X-100 in PBS containing 5 mg/mL Sambucus nigra
agglutinin (SNA, Vector Laboratories, Burlingame, CA). The
sections were washed with 0.05% Triton X-100 in PBS and
visualized with confocal microscope (Leica SP2). Three-dimen-
sional images were reconstructed with Imaris software (Bitplane
Scientific Software, Zurich, Switzerland).
Statistical analysis
All results were reported as means with standard deviation.
Statistical analysis was performed using one-way or two-way
ANOVA depending on the number of grouping factors. Group
Figure 1. Effect of HDAC silencing or inhibition on BxPC-3 cell proliferation. (A) Time-dependent and dose-dependent effects of SAHA on
cell proliferation. (B) Time-dependent effect of class IIa HDAC7 silencing on cell proliferation. HDAC7 expression was detected by western-blot 48h
after siRNA transfection. HSC70 was used as a loading control. (C) Time-dependent effect of class I HDAC1 or –3 silencing on cell proliferation.. HDAC1
and HDAC3 expression was detected by western-blot 48h after siRNA transfection. HSC70 was used as a loading control. (D) Time-dependent and
dose-dependent effects of MS-275 on cell proliferation ***P,.001 versus DMSO or GL3 conditions. Results are expressed as mean6 s.d., n$3 in each
condition.
doi:10.1371/journal.pone.0075102.g001
HDAC/COX-2 Coinhibition in a Pancreas Cancer Model
PLOS ONE | www.plosone.org 3 September 2013 | Volume 8 | Issue 9 | e75102
means were compared by a Bonferroni’s post-test. P,.05 was
considered as statistically significant. All experiments were
performed as 3 independent biological replicates.
Results
Class I HDAC inhibition reduced pancreas cancer cell
growth in vitro
BxPC-3 cells have been described to express altered levels of
class I HDAC1, HDAC3 and class II HDAC7 [40,41]. To
evaluate the role of these HDAC in BxPC-3 cells, we first
examined their time-dependent and concentration-dependent
growth in presence of SAHA, a class I/II inhibitor (Figure 1A).
Our results confirmed that BxPC-3 cells were sensitive to SAHA,
with a 50% growth reduction (P,.001) observed at 5 mM. Next,
we selectively silenced HDAC1, –3 or –7 using siRNA to examine
the individual involvement of these HDAC in the SAHA-induced
growth reduction. HDAC7 silencing did not affect cell growth
(Figure 1B). However, HDAC1 and HDAC3 silencing reduced
significantly BxPC-3 cell growth by respectively 50% (P,.001) and
20% (P,.001) (Figure 1C). In order to evaluate this decrease in
cell growth with clinically compatible drug, we evaluated the time-
dependent and concentration-dependent growth of BxPC-3 cells
in presence of MS-275 (HDAC1 and HDAC3 inhibitor). MS-275
(1 mM) reduced BxPC-3 cell growth by 50% (P,.001) whereas
5 mM abolished completely the growth (P,.001) (Figure 1D).
Class I HDAC inhibition induced COX-2 expression in
vitro
The limited efficiency of HDAC inhibitors in clinical trials
including PDAC patients could be explained, at least in part, by
the potential up regulation of the expression of COX-2 in
pancreatic malignant cells. To evaluate this hypothesis, we first
analyzed COX-2 expression in BxPC-3 cells silenced for HDAC1,
HDAC2, HDAC3 or treated with MS-275. HDAC1 or HDAC3
repression induced respectively a 6.3-fold and a 4.8-fold increase
of COX-2 expression at protein level (Figure 2A) while HDAC2
silencing reduced COX-2 expression (Figure 2B). HDAC1
silencing induced an HDAC2 overexpression.
Figure 2. Effect of HDAC silencing or inhibition on COX-2 expression in BxPC-3 cells. (A) Western-blot detection of COX-2 and HDAC in
20 mg BxPC-3 proteins 48h after HDAC1 or HDAC3 siRNA transfection. (B) Western-blot detection of COX-2 and HDAC in 20 mg BxPC-3 proteins 48h
after HDAC2 siRNA transfection. (C) Dose-dependent effects of 48h MS-275 treatment on COX-2 expression. Acetylated-histone H3 was used as a
control of treatment efficacy. HSC70 was used as a loading control. (D) Time-dependent relative expression of COX-2 mRNA in BxPC-3 cells treated
with 1 mM MS-275. Results are expressed as mean 6 s.d., n = 3.
doi:10.1371/journal.pone.0075102.g002
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Treatment of BxPC-3 cells with MS-275 showed similar effects
on COX-2 accumulation in a concentration-depend manner
(Figure 2C). To determine whether COX-2 induction occurs at
transcriptional level, we analyzed COX-2 mRNA level by RT-
qPCR following 6, 12, and 24h of MS-275 treatment. We found
that COX-2 gene expression was up-regulated following the MS-
275 treatment in a time-dependent manner (Figure 2D).
To study the mechanisms by which class I HDAC inhibition
induces COX-2, we explored the known link between NF-kB and
HDAC1/3 [42,43] and tested the possibility that MS-275-induced
COX-2 expression could be NF-kB dependent. Accordingly, we
co-treated cells with MS-275 and BAY-11-7082, an IkBa kinase
(IKK) inhibitor. BAY-11-7082 reduced by 30% to 90% the COX-
2 expression following respectively 6h to 48h of MS-275 treatment
(Figure 3A), suggesting the MS-275-induced expression of COX-2
is, at least in part, NF-kB dependent. This hypothesis was
supported by p65-silencing and p65 translocation to the nucleus.
COX-2 expression was induced by a 24h treatment with MS-275
and was prevented by p65 siRNA (Figure 3B). Moreover, 24h MS-
275 treatment induced an increase by 50% of the p65 protein level
in the cytoplasm and in the chromatin fraction of BxPC-3 cells
(Figure 3C). The same MS-275 treatment induced the gene
expression of IL-8 (Figure 3D), a direct target of NF-kB.
Combined inhibition of class I HDAC and COX-2 inhibits
cell growth in vitro
In order to validate our hypothesis that class I HDAC inhibition
mediated induction of COX-2 might contribute to the low
efficiency of HDAC based therapy in PDAC patients, we have
combined the latter with celecoxib, a selective COX-2 inhibitor at
IC50 (respectively 1 mM of MS-275 and 10 mM of celecoxib). The
MS-275-induced COX-2 overexpression led to a 50% increase of
PGE2 concentration in the culture media (Figure 4A). BxPC-3 cell
treatment with celecoxib alone or in combination with MS-275
reduced significantly the PGE2 concentration in the cell media.
We then analyzed the impact of these treatments on the cell
growth. The combination of the two drugs reduced significantly
(.85%, P,.001) the BxPC-3 cell growth in comparison with using
either drug alone (Figure 4B). We next asked the question whether
this reduction is due to induction of apoptosis and performed an
annexin V/propidium iodide staining at 24, 48 and 72h (Figure
4C) following the treatment. None of the individual drugs nor their
combination were able to induce apoptosis. These results were
Figure 3. Effect of HDAC inhibition on NF-kB activation in BxPC-3 cells. (A) Effect of an IKK inhibitor (10 mM BAY-11-7082) on 1 mM MS-275-
induced COX-2 expression. Phospho-IkBa was used as a control of BAY-11-7082 treatment efficacy. HSC70 was used as a loading control.
Densitometry was expressed as a COX-2/HSC70 or IkBa/HSC70 ratio. (B) Western-blot detection of COX-2 in 20 mg BxPC-3 proteins after 1 mM MS-275
treatment and p65 siRNA transfection. HSC70 was used as a loading control. (C) Western-blot detection of p65 in 15 mg BxPC-3 cytoplasm,
nucleoplasm or chromatin-associated proteins after 1 mM MS-275 treatment. MEK2 and ORC2 were used as a loading control respectively in
cytoplasm and chromatin fractions. Densitometry was expressed as a p65/MEK2 or p65/ORC2 ratio. (D) Time-dependent relative expression of IL-8
mRNA in BxPC-3 cells treated with 1 mM MS-275, 10 mM Celecoxib or a combination of the drugs. Results are expressed as mean 6 s.d. ***P,.001,
*P,.05 versus DMSO. n$3 in each condition.
doi:10.1371/journal.pone.0075102.g003
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confirmed by western-blot, showing intact caspase-3 in all samples
(Figure 4C). To further investigate the mechanisms of the observed
cell growth arrest, we next examined the effect of MS-275/
celecoxib combination on the cell cycle (Figure 4D). MS-275
alone, but not celecoxib, increased the proportion of cell in G1 by
50% at 48h. However, MS-275/celecoxib combination decreased
significantly (P,.001) the proportion of cells in S phase at 24 (–
74%), 48 (–92%) and 72h (–82%) and increased significantly
(P,.001) the proportion in G1 phase at 24 (+48%), 48 (+119%)
and 72h (+80%). To validate these results we analyzed by western
blot the expression of cell cycle markers and found a clear
accumulation of p21WAF1 and p27Kip1, two cell cycle inhibitors, at
24h and 48h after the co-administration of MS-275 and celecoxib
(Figure 4E). Consistently, the hyperphosphorylated form of pRb
was less abundant when BxPC-3 cells were co-treated with MS-
275/celecoxib. The hypophosphorylated form of pRb appeared
with the co-inhibition of class I HDAC and COX-2. The whole
pRb protein disappeared at 48h after the cotreatment. This
disappearance was already observed by others after a p21WAF1 or
p27Kip1 accumulation [44]. The E2F1 transcription factor, a S-
phase orchestrator, became undetectable 48h after co-administra-
tion of MS-275 and celecoxib. These results show that cellular
growth inhibition is associated to a G0/G1 phase blockage.
BxPC-3 is a PDAC cell line characterized by its KRAS
wildtype, while mutations of the gene coding for this protein is the
most common genetic alteration observed in human PDAC.
However, BxPC-3 cells overexpress COX-2, a situation noted in
50% of human PDAC. We have decided to extend our
observations regarding the interest of the combined treatment in
pancreatic cancer by examining the efficiency of such combined
treatment on two human pancreas cell lines with reported KRAS
mutations. The first cell line was PANC-1 ([12 ASP]-KRAS) in
which COX-2 was undetected at the protein level [45]. The
second cell line was CFPAC-1 ([12 VAL]-KRAS) but in which
COX-2 was detected at protein level [45].
PANC-1 cell line was cultured with MS-275, celecoxib or both
drugs in combination. Celecoxib 10 mM did not alter cell growth
when MS-275 1 mM reduced significantly (p,,001) cell growth by
32%. The combination of the two drugs reduced the PANC-1 cell
growth (49%, P,.001). However, the combination-induced
growth inhibition was not significantly different from the MS-
275-induced one (Figure 5A). In this cell line, MS-275 did not
induce the expression of COX-2 (data not shown).
CFPAC-1 cell line was cultured in the same conditions.
Celecoxib 10 mM reduced cell growth by 54% (p,,001) and
MS-275 1 mM reduced cell growth by 59% (p.,001). Here, the
Figure 4. Effect of HDAC and COX-2 coinhibition in BxPC-3 cells. (A) ELISA assay of PGE2 in cell culture media 24h and 48h after 1 mM MS-275
and 10 mM celecoxib treatment. (B) Time-dependent effects of MS-275 and celecoxib on cell growth. (C) Time-dependent effects of 1 mM MS-275 and
10 mM celecoxib on apoptotic cell ratio by annexin V/PI flow cytometry and on caspase-3 cleavage. (D) Time-dependent effects of 1 mM MS-275 and
10 mM celecoxib on cell cycle by PI incorporation. (E) Western-blot detection of p21, p27, pRb ppRb and E2F1 in 20 mg BxPC-3 proteins 6 to 48h after
1 mM MS-275 and 10 mM celecoxib treatment. HSC70 was used as a loading control. Results are expressed as mean 6 s.d., ***P,.001, **P,.01,
*P,.05 versus DMSO or indicated conditions. n$3 in each condition.
doi:10.1371/journal.pone.0075102.g004
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combination of the two drugs reduced significantly (79%, P,.001)
CFPAC-1 cell growth in comparison to either drug alone (Figure
5B). We then analyzed by western blot the expression of COX-2
and cell cycle markers in CFPAC-1 cells 48h after drugs
administration. We showed an MS-275-induced accumulation of
COX-2 like in BxPC-3 cells (Figure 5C). We found also an
accumulation of p21WAF1 and p27Kip1 after the co-administration
of MS-275 and celecoxib (Figure 5C), suggesting a cell cycle arrest.
BxPC-3 CAM tumor mimics human PDAC
The evaluation of new drugs or drug combinations for pancreas
cancer will be eased by the availability of easy, ethically and
economically sustainable animal models. Thus, we have under-
taken to refine a human pancreas chorioallantoic membrane
(CAM) model based on our initial work [32]. Embedding BxPC-3
cells into matrigel prior to CAM implantation generated a major
improvement in the tumor volume. Indeed, following implanta-
tion, the tumor volume increased linearly (r2 = 0.87) until day 7
(Figure 6A). At the time of tumor collection (day 7), an average
tumor volume of 59.95615.34 mm3 (n = 10) was observed. BxPC-
3 CAM tumors grew inside the CAM connective tissue as a unique
spheric nodule. The same procedure was followed for BxPC-3,
PANC-1 and CFPAC-1 cell lines. PANC-1 did not grow on CAM
when CFPAC-1 grew as very small nodules (1 mm long).
BxPC-3 CAM tumor histology (Figure 6B) revealed large islets
of cohesive cells, some of which showed a nascent central lumen
and were isolated from each other by a collagen-containing
extracellular matrix with several sparse fibroblast-like cells
demonstrating the presence of an interstitial stroma.
To further validate our human pancreas cancer CAM model,
we compared the expression of the cytokeratin-7, -19, -20, CD56,
CEA and Ki67 using immunohistochemistry to human PDAC.
We also checked for mucin and proteoglycan production utilizing
the PAS staining. Tumoral cells from both BxPC-3 CAM tumor
and PDAC samples were strongly positive for cytokeratin-7 and -
19, CEA and Ki67 (Figure 6C) but negative for cytokeratin-20 and
CD56 (data not shown). Both tumors were positive for PAS
staining. Altogether, the data showed remarkable histology and
biomarker expression similarities between the BxPC-3 CAM
model and PDAC from human patients.
Furthermore, our recent work on targetable biomarkers in
human PDAC [46] identified several biomarker candidates among
which myoferlin, transforming growth factor beta-induced and
latent-transforming growth factor beta-binding protein 2. Immu-
nohistochemistry and western-blot confirmed the presence of these
new PDAC biomarkers in the BxPC-3 CAM tumors (Figure 7A–
B). Finally, using western blot we confirmed that HDAC1,
HDAC2, HDAC3 and COX-2 are expressed in the BxPC-3 CAM
tumor (Figure 7A).
We next demonstrated that tumors were functionally vascular-
ized. BxPC-3 CAM blood vessels were stained by FITC-
conjugated SNA and 3D reconstructed after confocal acquisition.
BxPC-3 CAM tumors displayed blood vessels around pancreatic
islets (Figure 8A). The fluorescence of tumor stroma after
Figure 5. Effect of HDAC and COX-2 coinhibition in PANC-1 and CFPAC-1 cells. (A) Time-dependent effects of MS-275 and celecoxib on
PANC-1 cell growth. (B) Time-dependent effects of MS-275 and celecoxib on CFPAC-1 cell growth. (C) Western-blot detection of Cox-2, p21, p27 in
30 mg CFPAC-1 proteins 48h after 1 mM MS-275 and 10 mM celecoxib treatment. HSC70 was used as a loading control. Results are expressed as mean
6 s.d., ***P,.001 versus DMSO or indicated conditions. n$3 in each condition.
doi:10.1371/journal.pone.0075102.g005
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fluorescent dye injection in the CAM vasculature confirms that the
vessels are functional (Figure 8B) and the detection of desmin
positive pericytes suggests vessel stabilization (Figure 8C).
Next, BxPC-3 tumors were treated beginning day 2 either with
8 mM celecoxib or 0.2 mM MS-275 or with a combination of two
drugs at their respective concentrations. MS-275 concentration
was chosen to fit with the plasmatic concentration measured in
Human in a 5 mg/m2 weekly dosing schedule [15]. While
celecoxib alone did not affect tumor growth, MS-275 alone
induced a decreased of tumor growth by 50% (P,.001) and
induced the expression of COX-2. Combination of celecoxib and
MS-275 completely abolished (P,.001) tumor growth, leading to
no change in tumor volume compared to the beginning of
treatment (Figure 9A-B). Tumors treated with MS-275 overex-
pressed COX-2 (Figure 9C). Tumors treated with combination of
celecoxib and MS-275 revealed empty spaces inside the tumor.
(Figure 9D). We then asked the question whether this reduction of
tumor volume is due to induction of apoptosis or to proliferation
arrest. Tumors treated with MS-275, celecoxib or both drugs were
submitted to a cleaved caspase-3 detection and were labeled for
Ki67. The full-length caspase-3 was detected in all samples but no
cleaved caspase-3 was observed (Figure 9E). The relative Ki67-
positive area was slightly but significantly reduced by the
combination of HDAC and COX-2 inhibitors (Figure 9F).
Discussion
The potential interest of anti-HDAC treatment strategies for
PDAC is supported by several preclinical studies [18,19,22,47–
50]. In agreement with these studies, we showed that pan-HDAC
inhibitor SAHA was able to reduce significantly pancreatic cancer
cell growth. Following the rationale that HDAC7, HDAC3 and
HDAC1 have been reported to be over-expressed in the PDAC
[8–10] we have examined their individual roles with respect to
their ability to control BxPC-3 cell growth. The results demon-
strated that HDAC7 silencing was unable to decrease the cell
growth while HDAC1 and HDAC3 inhibition or silencing
reduced significantly the BxPC-3 cell growth highlighting the
importance of these enzymes in PDAC patients. However, the
results of clinical studies where HDAC inhibitors are used show
only limited or no ability to affect tumor development [3,13]. This
is likely to be related to the pleiotropic activities of HDAC
including some that might promote tumor progression. In this line,
HDAC1, –2 and –3 may have been shown to regulate the function
of RelA/p65 subunits of NF-kB. Class I HDAC1 can indeed
interact with RelA/p65 acting as a corepressor to negatively
Figure 6. Growth curve and immunohistologic characterization of BxPC-3 tumors grown on CAM. (A) Cells were implanted on CAM at
embryonic day 11 and collected 2, 4, 5, 6 or 7 days after implantation. Macroscopic pictures were obtained at the same magnification from top,
bottom and side view. Results are expressed as mean 6 s.d., n.5 at each time-point. (B) Histologic (Haematoxylin-Eosin or Masson’s trichrome
staining) analysis of tumors collected 2, 4, 5, 6 or 7 days after implantation. (C) Immunohistology of tumors 7 days after BxPC-3 implantation on CAM
and human PDAC tumors. CK7 = Cytokeratin-7, CK19 = cytokeratin-19, CEA = Carcinoembryonic antigen, PAS = Amylase-periodic acid Schiff
staining.
doi:10.1371/journal.pone.0075102.g006
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regulate its transcriptional activity [43]. HDAC3-mediated
deacetylation of RelA/p65 promotes its binding to IKBa leading
to cytosolic sequestration [42] and NF-kB repression. In parallel,
HDAC2 was also overexpressed in PDAC and was shown to
regulate NF-kB activity without direct interaction with p65 [43].
As a consequence, class I HDAC inhibition could induce the
transcriptional activation of NF-kB-driven genes. Consistently, a
significant COX-2 induction was recently showed in lung cancer
cells following trichostatin A or SAHA treatment [27]. Here, we
showed, for the first time, that the class I HDAC chemical
inhibitor MS-275 and selective silencing of both HDAC1 and
HDAC3 are able to induce the transcription of COX-2 gene and
the accumulation of the functional enzyme independently of the
KRAS status. Conversely, HDAC2 silencing does not elicit COX-
2 accumulation but reduce its expression. COX-2 is considered to
be part of the positive feedback loop amplifying Ras activity to a
pathological level causing inflammation and cancer [51]. More-
over, COX-2 was demonstrated to confer a growth advantage to
pancreatic cancer cells [52]. These results together with our
findings suggest the potential interest in inhibiting COX-2 activity
while subjecting COX-2 positive (about 50-60% of the cases [53])
PDAC patients to anti-HDAC treatments. This can be easily
achieved because several molecules, including the celecoxib [54],
were developed in order to inhibit specifically COX-2. Celecoxib
was found to significantly decrease or delay pancreatic cancer
progression in animal model [29,55]. Keeping these findings in
mind, we combined class I HDAC and COX-2 inhibitors and test
their efficiency to control tumor growth. The co-treatment
reduced the pancreas cancer cell growth by blocking cells in
G0/G1 state. This is probably a mechanism that could explain the
effects observed in vivo, where the combination of two drugs
completely stalled the tumor growth. Importantly, the inhibition of
tumor growth was observed with drug concentrations 10-fold
lower than the concentrations needed if the drugs were used
individually [56,57]. This represents a considerable advantage for
a putative clinical use regarding the possible undesired effects.
However, the in vivo model used in this work remains very simple
compared to the complexity of the pathology in human.
Moreover, the cell line used to grow the tumor in ovo is a
limitation as it does not harbor constitutively active Kras which is
the most common genetic alteration in human PDAC. In
consequence, in vivo studies in genetically-engineered mouse
models of PDAC are more than necessary before entering
potential clinical trials with combined treatment, especially in
the case of patients harboring KRAS mutation. Several models are
now available to recapitulate the disease [58].
One additional outcome of the current study is the development
and characterization of a refined animal model of PDAC
recapitulating all the main features observed in human tumors.
We have based our development on a model we previously set-up
[32] but which did not provide with the possibility to efficiently test
experimental therapies. Following extensive method development
Figure 7. Biomarker detection in tumors 7 days after BxPC-3
implantation on CAM. (A) Western-blot detection of HDAC1, HDAC2,
HDAC3, HDAC7, COX-2, TGFBI, MYOF, LTBP2 in 20 mg PDAC-CAM or
BxPC-3 proteins. HSC70 was used as a loading control. (B) Immunoper-
oxydase labelling of MYOF, TGFBI, LTBP2, COX-2.
doi:10.1371/journal.pone.0075102.g007
Figure 8. Blood vessel detection in tumors 7 days after BxPC-3 implantation on CAM. (A) Imaris 3D reconstruction from a 35 mm stacked
image after SNA staining (green). Nuclei were counter stained with DAPI (blue). (B) Confocal image after FITC (green) injection in CAM blood vessels.
Nuclei were counter stained with TOPRO (blue) (C) Desmin immunodetection (red) in PDAC-CAM stained with SNA (green). Nuclei were counter
stained with DAPI (blue).
doi:10.1371/journal.pone.0075102.g008
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we have established means to produce larger tumors, bearing fully
functional blood vessels. The clinical relevance of this improved
model is supported by the CK7+/CK19+/CK20-/CEA+/Ki67+/
CD562 immunodetection. CK7 and CK20 expression has been
shown to be useful in the differential diagnosis of several
carcinomas of epithelial origin. According to Lee et al. [59] 95%
of PDAC are CK7+, 100% are CK19+ and 73% are CK202. In
pancreas carcinomas the proportion of cells stained for CEA and
the Ki-67 index were respectively increased 3-fold and 10-fold in
comparison with the normal tissue [60,61]. CD56 staining was
found negative in all cases of human PDAC [62]. These
biomarkers, together with the presence of mucin are the main
hallmarks of PDAC [63].
Recently, we have discovered several biomarkers of human
PDAC that bare therapeutic potential [46]. These antigens were
also present in our CAM tumor model, supporting its similarity
with human cancer and providing the research community with a
rapid and cost effective model for pancreas cancer research such as
our present demonstration of the benefit to combine COX-2 and
HDAC inhibition for optimal anti tumor activity.
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